Alzheon’s Alzheimer’s Pill Fails in Phase III Trial

US-based Alzheon’s Alzheimer’s disease pill has failed in a Phase III trial, but the biopharma still holds hope for the drug after seeing signals in a subgroup of patients. The company said that while valiltramiprosate did not meet the primary endpoint in the pivotal APOLLOE4 study, nominally statistically significant and clinically meaningful cognitive benefits were observed in Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13), in a prespecified group of patients who could benefit from early intervention. The company has not confirmed its regulatory plans for Alzheon’s Alzheimer’s drug based on the Phase III data.